Search

Displaying results 3321 - 3330 of 4575 in total
  1. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  2. Drug

    Moricizine

    go.drugbank.com/drugs/DB00680
    ApprovedWithdrawn

    An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

  3. Drug

    Foscarnet

    go.drugbank.com/drugs/DB00529
    ApprovedInvestigational

    An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.

  4. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  5. Drug

    Gentian violet cation

    go.drugbank.com/drugs/DB00406
    Approved

    A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.

  6. Drug

    Dopamine

    go.drugbank.com/drugs/DB00988
    ApprovedInvestigational

    One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regu...

  7. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

  8. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.

  9. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition

  10. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial.